Europe Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet’s Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Peripher

Europe Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet’s Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Peripheral Arterial Tonometry (PAT), Venous Occlusion Pletismography, Circulating Markers, and Others)], and End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others)

The Europe endothelial dysfunction market is expected to grow from US$ 611.28 million in 2022 to US$ 776.37 million by 2028. It is estimated to grow at a CAGR of 4.1% from 2022 to 2028.

Rising Incidences of High Cholesterol, Diabetes and Obesity Fuels Europe Endothelial Dysfunction Market

Lifestyle changes lead to a rise in the incidences of diabetes, hypertension, dyslipidemia, and obesity, increasing the chances of endothelial dysfunction. However, these can be prevented through proactive monitoring, early diagnosis, and physical activity. Metabolic syndrome is a group of disorders that increases the risk of CAD, diabetes, high blood pressure, and other serious health problems. Type 2 diabetes is already a major public health problem and is increasingly rising among the children and young adults associated with obesity. According to the World Health Organization (WHO), diabetes was the direct cause of 1.5 million deaths in 2019, and 48% of all deaths from diabetes occurred before age 70. Another 460,000 deaths from kidney disease were caused by diabetes. Elevated blood sugar causes ~20% of cardiovascular deaths.

Hypertension is the leading cause of cardiovascular disease and premature death worldwide. The number of adults aged 30–79 with hypertension has increased from 650 million to 1.28 billion over the past 30 years, according to the first comprehensive global analysis of trends in the prevalence, detection, treatment, and control of hypertension among the population, headed by Imperial College London and WHO.

Europe Endothelial Dysfunction Market Overview

The endothelial dysfunction market in Europe is sub-segmented into the UK, Germany, Italy, France, Spain, and the Rest of Europe. The rising prevalence of cardiovascular diseases, an increase in the aging population, and a growing number of research and development activities are the key factors contributing to the market growth in the region. Further, product launches and government investments would facilitate the market growth during the forecast period.

Europe Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)

Europe Endothelial Dysfunction Market Segmentation

The Europe endothelial dysfunction market is segmented into cause, test type, end user, and country.

Based on cause, the Europe endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest Europe endothelial dysfunction market share in 2022.

Based on test type, the Europe endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger Europe endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the Europe endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest Europe endothelial dysfunction market share in 2022.

Based on country, the Europe endothelial dysfunction market is segmented into the UK, Germany, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe endothelial dysfunction market in 2022.

ZOLL Medical Corp, Sphingo Tec GmbH, The Polymath Co, SMART Medical Ltd, Alam Medical SaRl, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe endothelial dysfunction market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe endothelial dysfunction market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the endothelial dysfunction market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution